Grant A. McArthur
The University of Melbourne · 918 works · 80,473 citations · h-index 103
Top works
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
- Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
- RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
- Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
- Oncogenic Signaling Pathways in The Cancer Genome Atlas
- Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study
- Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
- Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer
- RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors